A Prospective, Phase 2a Study to Evaluate the Effectiveness and Safety of DPCP Ointment (Samcyprone™) on the Clearance of Verruca Vulgaris (Common Warts) in Subjects Ages 18 - 65 Years
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 26 Feb 2018
At a glance
- Drugs Diphencyprone (Primary)
- Indications Warts
- Focus Therapeutic Use
- Sponsors RXi Pharmaceuticals
- 23 Feb 2018 Planned End Date changed from 1 Jun 2017 to 1 May 2018.
- 08 Nov 2017 According to a RXi Pharmaceuticals media release, the company expects early read-outs before the end of this year.
- 06 Sep 2017 Status changed from recruiting to active, no longer recruiting, according to an RXi Pharmaceuticals Corporation media release.